Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImmunityBio Inc.

https://immunitybio.com/

Latest From ImmunityBio Inc.

Finance Watch: Rivus Raises $132m In Series B Cash To Fund Obesity Drug Trials

VC funding slowed recently, but public company financings kept up a brisk pace with follow-on public offerings for Allakos and Alpine, private placements for Ventyx and Syros, and Albireo’s royalty deal. In restructuring updates, Biogen raised $592m in a real estate deal and Acerus is assessing options.

Financing Growth

Next-Gen Vaccine Makers Want Up-Front Discussions With US FDA To Expedite Development

Early conversations on clinical trial endpoints were particularly helpful in developing Comirnaty, a Pfizer executive said. Whether sponsors can continue to get such discussions may go a long way in determining whether a new generation of products is developed.

Coronavirus COVID-19 Vaccines

Finance Watch: Amylyx, CinCor And Vigil Ready The First Biopharma IPOs Of 2022

Public Company Edition: Mergers with special purpose acquisition corporations also continue to take companies public, with three new SPAC offerings in late 2021. Also, Xeris raised $30m in a private placement of stock to support its recently approved drug and Sirnaomics went public in Hong Kong.

Financing Deals

Where Next For Sesen Bio’s Bladder Cancer Therapy Vicineum?

A complete response letter from the FDA has dashed Sesen Bio’s hopes of being first with a therapy for treating BCG-unresponsive non-muscle invasive bladder cancer. Its CEO says the FDA’s move may reflect heightened ‘pressure’ regulator is under.

Regulation Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • Conkwest, Inc.
    • NantKwest, Inc.
UsernamePublicRestriction

Register